reports
CRISPR Therapeutics to Present at the Jefferies London Healthcare Conf...
CRISPR Therapeutics to Present at the Jefferies London Healthcare Conference ZUG, Switzerland and BOSTON, Nov. 14, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that Samarth Kulkarni, Ph.D., Chief Executive Officer and Chairman of CRISPR Therapeutics, will present at the Jefferies London Healthcare Conference on Wednesday, November 20, 2024, at 4:00 p.m. GMT. A live webcast of the fireside chat will be available on the "Events & Presentations" page in t...
CRISPR Therapeutics AG: 1 director
A director at CRISPR Therapeutics AG sold 30,000 shares at 55.623USD and the significance rating of the trade was 70/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years ...
- Jacob Mekhael
Autolus FIRST LOOK: 3Q24 update focusses on Aucatzyl's launch in r/r a...
Yesterday before US market opens, Autolus reported 3Q24 results with a cash position of $657.1m (YE23: $239.9m), sufficient to drive Aucatzyl's (obe-cel, CD19 CAR-T) launch in r/r adult ALL, and advance the company's pipeline towards pivotal autoimmune data (KBCSe 2028). The focus of the 3Q24 update was Aucatzyl's upcoming launch, and we expect the large safety differentiation vs. Tecartus to be a key factor for adoption. In parallel, we look forward to initial autoimmune data in 1Q25, which has...
- Jacob Mekhael
- Michiel Declercq
- Thibault Leneeuw
- Thomas Couvreur
- Wim Lewi
Autolus Therapeutics Reports Third Quarter 2024 Financial Results and ...
Autolus Therapeutics Reports Third Quarter 2024 Financial Results and Business Updates AUCATZYL® (obecabtagene autoleucel) approved by US FDA on November 8, ahead of target PDUFA date of November 16; US commercial launch initiatedBLA approval triggers $30m milestone payment to Autolus from Blackstone Marketing authorizations for obe-cel under review with both the MHRA EMAMatthias Will M.D. appointed as Chief Development Officer, effective September 30, 2024Conference call to be held today at 08:30 am EDT/13:30 pm BST: conference call participants should pre-register using the link at the bo...
- Jacob Mekhael
Autolus Christmas came early! CAR-T hits the road with FDA approval in...
Our life sciences top pick Autolus secured FDA approval for Aucatzyl (obe-cel, CD19 CAR-T) in r/r adult B-ALL ahead of the scheduled PDUFA date of 16 November. In our view Aucatzyl has a best in class safety profile, and the absence of a requirement for a REMS program from the FDA provides further validation of its differentiated safety. Based on KOL feedback, Aucatzyl's safety profile will be a key driver for adoption, and we think no REMS will give this a further boost! We look forward to the ...
Autolus Therapeutics Announces FDA Approval of AUCATZYL® (obecabtagene...
Autolus Therapeutics Announces FDA Approval of AUCATZYL® (obecabtagene autoleucel – obe-cel) for adults with relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL) AUCATZYL is the first CAR T therapy approved by the FDA with no requirement for a REMS program (Risk Evaluation Mitigation Strategy)Approval based on FELIX clinical trial of obe-cel in adult patients with r/r B-ALLConference call to be held on November 11 at 08:30 am EST/13:30 pm BST: conference call participants should pre-register using the link at the bottom of this press release LONDON, Nov. 08, 2024 (GLOB...
CRISPR Therapeutics to Present at the Guggenheim Inaugural Healthcare ...
CRISPR Therapeutics to Present at the Guggenheim Inaugural Healthcare Innovation Conference ZUG, Switzerland and BOSTON, Nov. 07, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that Samarth Kulkarni, Ph.D., Chief Executive Officer and Chairman of CRISPR Therapeutics, will present at the Guggenheim Inaugural Healthcare Innovation Conference on Tuesday, November 12, 2024, at 2:00 p.m. ET. A live webcast of the fireside chat will be available on the "Events...
Monthly information on share capital and company voting rights
Monthly information on share capital and company voting rights (Article 223-16 of General Regulation of the French financial markets authority) PARIS, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 DateTotal number of sharesin the capitalTotal number of voting rights10/31/2024100,093,87388,569,210 For further information on Cellectis, please contact: Media contact: Pascalyne Wilson, Director, Communications, +33 (0)7 76 99 14 33, Patricia Sosa Navarro, Chief of Staff to the CEO, +33 (0)7 76 77 46 93 Investor Relations contac...
Information mensuelle relative au nombre total des droits de vote et d...
Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social (Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers) PARIS, 06 nov. 2024 (GLOBE NEWSWIRE) -- Place de cotation : Euronext Growth ISIN code: FR0010425595 DateNombre total d’actions composant le capital socialNombre total de droits de vote31/10/2024100 093 87388 569 210 Pour de plus amples informations sur Cellectis, veuillez contacter : Contact média : Pascalyne Wilson, Director, Communications, +33 (0)7 76 99 14 33, Patricia Sosa ...
- Jacob Mekhael
ASH abstracts Autolus, Galapagos, MaaT
The abstracts for presentations at ASH (7-10 December) became available yesterday during the day (here). While we may have to wait until the actual conference for the latest datasets, here in this note are some key takeaways for our coverage including updates from Autolus (digging deeper into the obe-cel dataset), Galapagos (more CAR-T data and pre-clinical data on TCR-T) and MaaT (early access program in aGvHD):
Cellectis présente de multiples stratégies pour améliorer l'efficacité...
Cellectis présente de multiples stratégies pour améliorer l'efficacité des cellules CAR T dans les tumeurs solides à la réunion annuelle de la SITC NEW YORK, 05 nov. 2024 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), société de biotechnologie de stade clinique, qui utilise sa technologie pionnière d'édition de génome TALEN® pour développer des thérapies innovantes pour le traitement de maladies graves, a annoncé aujourd’hui que des données précliniques pour améliorer l'activité des cellules CAR T contre les tumeurs solides tout en prévenant la toxicité potentiell...
Cellectis Presents Multiple Strategies to Enhance CAR T-cell Efficacy ...
Cellectis Presents Multiple Strategies to Enhance CAR T-cell Efficacy in Solid Tumors at the SITC Annual Meeting NEW YORK, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today that pre-clinical data to enhance CAR T cell activity against solid tumors while preventing potential toxicity, will be presented at the Society for Immunotherapy of Cancer’s 39th Annual Meeting (SITC), that will take place ...
CRISPR Therapeutics Provides Business Update and Reports Third Quarter...
CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results -CASGEVY™ approved for the treatment of patients 12 years of age and older with sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT) in Switzerland and Canada- -45 authorized treatment centers (ATCs) activated globally for CASGEVY and approximately 40 patients have had cells collected across all regions as of mid-October- -Two clinical trials are ongoing for next generation CAR T product candidate, CTX112™ targeting CD19, in B-cell malignancies and systemic lupus erythematos...
Autolus Therapeutics to Present Clinical Data Updates at the American ...
Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2024 in One Oral Presentation and Three Poster Presentations LONDON, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, announces the online publication of four abstracts submitted to the American Society of Hematology (ASH) Annual Meeting, to be held from December 7-10, 2024, in San Diego. “The FELIX study’s rich data set continues to provide importan...
Cellectis Provides Business Updates and Financial Results for Third Qu...
Cellectis Provides Business Updates and Financial Results for Third Quarter 2024 UCART22 and UCART20x22: enrollment ongoing, Phase 1 dataset and late-stage development strategy to be presented in 2025AstraZeneca partnership: R&D activities are ongoing on three programs – one allogeneic CAR T for hematological malignancies, one allogeneic CAR T for solid tumors, and one in vivo gene therapy for a genetic disorderAppointed Adrian Kilcoyne, M.D., MPH, MBA, an industry leader in the advancement of cell therapy treatment, as Chief Medical OfficerCash position of $264 million as of September 30, ...
Cellectis présente ses résultats financiers du troisième trimestre 202...
Cellectis présente ses résultats financiers du troisième trimestre 2024 et une mise à jour de ses activités UCART22 et UCART20x22 : recrutement de patients en cours, un ensemble de données de la Phase 1 et la stratégie de développement seront présentées en 2025Partenariat avec AstraZeneca dans le domaine des CAR T allogéniques et de l'édition du génome in vivo : des activités de R&D sont en cours sur trois programmes - un CAR T allogénique pour les hémopathies malignes, un CAR T allogénique pour les tumeurs solides et une thérapie génique in vivo pour une maladie génétiqueNomination du doct...
Cellectis to Report Third Quarter 2024 Financial Results on November 4...
Cellectis to Report Third Quarter 2024 Financial Results on November 4, 2024 NEW YORK, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report financial results for the third quarter 2024 ending September 30, 2024 on Monday, November 4, 2024 after the close of the US market. The publication will be followed by an investor conference call and webcast on Tuesday, November 5, 2024 at...
Cellectis publiera ses résultats financiers du troisième trimestre 202...
Cellectis publiera ses résultats financiers du troisième trimestre 2024 le 4 novembre 2024 NEW YORK, 30 oct. 2024 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), société de biotechnologie de stade clinique qui utilise sa technologie pionnière d’édition du génome TALEN® pour développer des thérapies innovantes pour le traitement de maladies graves, publiera ses résultats financiers pour le troisième trimestre se terminant au 30 septembre 2024, le lundi 4 novembre 2024 après la clôture du marché aux États-Unis. Une conférence téléphonique se tiendra mardi 5 novembre ...
Autolus Therapeutics to Report Third Quarter 2024 Financial Results an...
Autolus Therapeutics to Report Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024 LONDON, Oct. 28, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it will release its third quarter 2024 financial results and operational highlights before open of US markets on Tuesday, November 12, 2024. Management will host a conference call and webcast at 8:30 am EDT/1:30 pm BST to discuss the company’s financial results and provide a g...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.